scholarly journals SKIN MICROBIOTA AND ATOPIC DERMATITIS IN CHILDREN: NEW TREATMENT OPTIONS

Author(s):  
Galina I. Smirnova ◽  
D. B. Munblit ◽  
A. I. Kolotilina ◽  
D. M. Levina

There are presented data characterizing atopic dermatitis (AD) in children as a form of allergic pathology, directly related to the condition and quality of the microbiota (intestinal and skin) of the growing organism. The microbiota of the affected skin of AD patients is characterized by a small species diversity of bacteria; the decrease in the number of actinomycetes and proteobacteria; increased colonization by various types of staphylococci (etc.). The relationship between the rate of formation of AD and the disturbance of the skin microbiota in children has been established. The concept of the preservation of high biodiversity of microbiota of a growing organism as a strategy for optimizing microecology of children by using adaptive probiotics in a healthy microenvironment is proposed. The restoration of the barrier function of the skin is determined as the most important task included in the general concept of the treatment of AD, where a significant role is assigned to new means of dermatological cosmetics and proper skin care. The possibilities of normalization the microbiota of affected areas of the skin with the help of cosmetic means for the care of dry skin are shown as a result of the restoration of the skin barrier.

Author(s):  
Galina I. Smirnova ◽  
A. A. Korsunsky

The review presents the special significance of changes in the intestinal and skin microbiota in the formation of atopic dermatitis (AD) in children. AD is considered as a form of allergic pathology directly related to the state and quality of the microbiota of a growing organism. The microbiota of the skin of patients with AD is characterized by a small species diversity of bacteria; a decrease in the number of actinomycetes and proteobacteria; increased colonization of various types of staphylococci (S. aureus, S. epidermidis, S. haemolyticus, etc). The relationship between the rate of development of AD and violations of the microbiota of the skin in children is shown. The necessity of maintaining high biodiversity of the microbiota of a growing organism as a strategy for optimizing the microecology of children through the use of adaptive probiotics in a healthy microenvironment is substantiated. The restoration of the barrier function of the skin and the normalization of the composition and quality of the intestinal microbiota are determined as the most important task of the general concept of the treatment of AD, where new dermatological cosmetics and proper skin care play an important role. The possibilities of normalizing the microbiome of the affected skin areas to restore the skin barrier with the help of dry skin care cosmetics are shown.


2018 ◽  
Vol 22 (1_suppl) ◽  
pp. 21S-29S ◽  
Author(s):  
Gurbir Dhadwal ◽  
Lorne Albrecht ◽  
Robert Gniadecki ◽  
Yves Poulin ◽  
Jensen Yeung ◽  
...  

The objectives of therapy for atopic dermatitis (AD) are to reduce skin inflammation and pruritus, restore skin barrier function, and improve quality of life (QoL). Treatments can be classified as moisturizing and basic care, topical therapy, phototherapy, and systemic therapy. In this review, we summarize the treatments for AD and recommendations for their use.


2016 ◽  
Vol 21 (1) ◽  
pp. 31-39 ◽  
Author(s):  
Melinda Gooderham ◽  
Charles W. Lynde ◽  
Kim Papp ◽  
Marc Bourcier ◽  
Lyn Guenther ◽  
...  

Background: Atopic dermatitis (AD) is a chronic, pruritic inflammatory skin disease resulting from defects in skin barrier and aberrant immune responses. AD significantly affects the quality of life. Not all patients respond to topical therapies, and often systemic therapy is required to control the disease. Objective: To review the treatment options for adult AD patients including those options for patients who do not respond adequately or have contraindications to oral systemic therapy. Methods: A working group of clinicians with experience managing AD was convened to review the current literature on treatment options for adult AD patients. This review is based on the best available evidence from a published systematic review and an additional literature search. Results: Current treatments for AD are reviewed, including options for adult AD patients who do not respond or have contraindications to current systemic therapies. A new approach with targeted therapies is reviewed based on best available evidence. Conclusion: Many AD patients respond satisfactorily to topical or systemic treatments, but for those patients who do not respond or have contraindications, new biologic agents appear to be promising therapies.


1995 ◽  
Vol 15 (3) ◽  
pp. 70-72 ◽  
Author(s):  
LT Swanson

The congenital heart defect of HLHS is nearly uniformly fatal without intervention. As surgeons gain experience with the techniques the success rates are improving; more infants with HLHS are being offered hope for survival and quality of life. The critical nature of this diagnosis, the relatively new treatment options, and uncertainty of the surgical outcome impose tremendous stress on the parents. Choice of treatment is difficult and should be made in collaboration with the attending physician. Although the first year of my son's life was difficult, the past 5 years have been wonderful. He continues to thrive and enjoy most of the activities other 6-year-olds enjoy. In retrospect, palliative surgery was a good option for him. As both his mother and a cardiac nurse, I recognize that he may once again require surgical intervention, but I am encouraged that medical and surgical advances are being made for children with HLHS.


2019 ◽  
Vol 23 (5_suppl) ◽  
pp. 19S-31S
Author(s):  
Perla Lansang ◽  
Joseph M. Lam ◽  
Danielle Marcoux ◽  
Vimal H. Prajapati ◽  
Shanna Spring ◽  
...  

Because atopic dermatitis (AD) is a chronic, relapsing disease, treatment requires the use of both active therapy to control flares and preventative maintenance therapy to promote integrity of the skin barrier. In this third of four sections, important clinical considerations for the treatment of pediatric AD are reviewed. Emerging therapies in development for pediatric AD are introduced.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 1340-1340 ◽  
Author(s):  
Mary L. Thomas ◽  
Kathleen Heptinstall ◽  
Audrey Hassan

Abstract Most physicians presume their relationship with the patient is a crucial component when managing chronic illness, such as myelodysplastic syndromes (MDS). This assumption was validated in a convenience sample of 70 adults with MDS who participated in five focus groups throughout the United States. The primary purpose of this qualitative study was to explore the impact of MDS on patients’ quality of life (QOL). The groups were facilitated by an advanced practice nurse with clinical expertise in MDS and qualitative research experience. Given the exploratory nature of the study design, discussions proceeded in differing directions; however, core questions were asked at each session (based on Ferrell’s work exploring QOL in patients with cancer (Oncology Nursing Forum, 1996). Sessions were audio-taped and professionally transcribed. Transcripts were coded and emerging themes identified using thematic analysis methods aided by the qualitative analysis program N5 (QSR International). The sample was 93% Caucasian, 51% male, with a mean age of 69 ± 9 years; 26% lived alone. Known MDS subtype was: 19 RA, 19 RARS, 11 RAEB, 3 5q-, 2 other (16 unknown); median time since diagnosis was 26 months (3 - 276). 73% received growth factors, 61% transfusions, 19% azacitidine, 16% thalidomide, 14% iron chelation; 29% all other; many patients received multiple (often concurrent) therapies. A significant finding from the focus groups revealed a detailed depiction of the patient-physician relationship from the patient’s perspective (discussed by 46 of the 62 patients who actively participated). Patients acknowledged many barriers that interfered with the relationship. These barriers were system related (e.g., extreme time constraints for physicians, priority to others who were more ill) or treatment related (e.g., lack of cure, limited treatment options). In addition, patients identified physician attributes that adversely impacted the relationship, including seeming indifference to the patient’s concerns, displays of arrogance, limited knowledge about MDS and its treatment, and especially, lack of confidence in managing the illness. In contrast, positive physician attributes that enhanced the relationship included: providing comprehensible explanations, willingness to seek assistance or opinions from MDS experts when the physician was unsure of the best treatment approach, and displays of compassion and concern. Patients identified displaying respect and interest in them as individuals as essential elements in establishing and maintaining a therapeutic relationship. Patients reacted to a difficult patient-physician relationship in various ways. Those patients who ascribed to the view that a physician had a revered position and was not to be challenged tended to suffer in silence, and remained anxious or depressed. Other patients described a more proactive position, where they continually sought new information about the disease and managing side effects and even felt responsible to explore other treatment options. However, this approach required much work and energy, and did not consistently alleviate the patient’s anxiety. MDS is a complex disease, where advances in understanding its pathology and identifying new treatments are beginning to have an impact in routine clinical practice. Data from this study suggest that physicians need to be aware of the barriers present in the patient-physician relationship and strive to ameliorate them. In so doing, patient’s anxiety, depression, and hyper-vigilance may be diminished, and quality of life enhanced.


2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Ting Ji ◽  
Xueliang Li ◽  
Lin Lin ◽  
Liuqin Jiang ◽  
Meifeng Wang ◽  
...  

Functional dyspepsia is of high prevalence with little treatment options. The aim of this study was to develop a new treatment method using self-management transcutaneous electroacupuncture (TEA) for functional dyspepsia (FD). Twenty-eight patients with FD were enrolled and underwent a crossover clinical trial with 2-week TEA at ST36 and PC6 and 2-week sham-TEA at nonacupuncture sham-points. Questionnaires were used to assess symptoms of dyspepsia and quality of life. Physiological testing included gastric emptying and electrogastrography. It was found that (1) TEA but not sham-TEA significantly improved dyspeptic symptoms and 4 domains in quality of life; improvement was also noted in self-rated anxiety and depression scores; (2) gastric emptying was significantly and substantially increased with 2-week TEA but not sham-TEA; and (3) gastric accommodation was also improved with TEA but not sham-TEA, reflected as increased ingested nutrient volumes at the levels of satiety and maximum tolerance. These findings suggest a therapeutic potential of self-administrated TEA method for functional dyspepsia, possibly attributed to improvement in gastric motility.


2009 ◽  
Vol 26 (2) ◽  
pp. 143-149 ◽  
Author(s):  
Ayelet Shani-Adir ◽  
Dganit Rozenman ◽  
Aharon Kessel ◽  
Batya Engel-Yeger

2021 ◽  
Vol 97 (5) ◽  
pp. 266-272
Author(s):  
Bernadett Hidvégi ◽  
◽  
Lilla Mihályi

Chronic urticaria is a multifactorial disease with increasing prevalence, that significantly deteriorates the quality of life of patients. Authors describe the pathomechanism of the disease, and they present the currently available treatment options and the promising future therapies as well. The therapeutic basis of chronic urticaria is the modern, 2nd generation antihistamines in a dosage of even four times higher than the regular one. In therapy resistant cases omalizumab or cyclosporin is advised. There is a growing demand for new medications because the number of those patients , who are non-responders or do not respond adequately to these therapies, is definitely increasing.


Sign in / Sign up

Export Citation Format

Share Document